Legend Biotech gains after Q1 2026 results highlight $597M CARVYKTI sales growth
Legend Biotech reported first-quarter 2026 results on May 12, 2026, highlighting CARVYKTI net trade sales up 62% year over year to about $597 million. The company also said cash, cash equivalents and time deposits were $834.6 million as of March 31, 2026.
1. Today’s catalyst (May 12, 2026)
Legend Biotech released its first-quarter 2026 results and recent highlights on May 12, 2026, a same-day fundamental catalyst. The update emphasized CARVYKTI net trade sales growth of 62% year over year to approximately $597 million and provided updated financial metrics, including a March 31, 2026 cash position of $834.6 million. (investors.legendbiotech.com)
2. What the update emphasized
The release pointed to broader global availability (18 markets) and operational progress around manufacturing performance and turnaround times, alongside the CARVYKTI sales growth figures. It also referenced milestones totaling $55 million achieved in April 2026 tied to the Janssen collaboration framework. (investors.legendbiotech.com)
3. Why this can move the stock today
Earnings-day disclosures can reset near-term expectations around demand, commercialization scale, margins, and runway, especially for a company where CARVYKTI performance is the central value driver. With the results published during U.S. market hours on May 12, 2026, this qualifies as a concrete same-day news catalyst for LEGN’s move.